No Data
No Data
Spike Health (00314) subsidiary further subscribes to China Construction Bank wealth management products with a capital of 100 million yuan
Spai Health (00314) announced that on April 16, 2024, Shipai Health Industry Investment, a wholly-owned subsidiary of the company, has subscribed to wealth management products with a capital of 100 million yuan provided by China Construction Bank. On April 24, 2024, Spai Health Industry Investment further subscribed to wealth management products with a capital of 100 million yuan provided by China Construction Bank.
SIPAI HEALTH: 2023 Annual Report
Announcement Highlights: Xiaomi Q4's adjusted net profit increased 236.1% year on year; Xiaopeng Motor Q4's adjusted net loss decreased by 19.9% year on year
Li Ning's revenue in 2023 was 27.598 billion yuan, an increase of 7.0%; China Unicom's profit due to equity holders in 2023 was 18.7 billion yuan, an increase of 11.8% over the previous year.
Spai Health (00314) announced annual results. Shareholders' losses of 256 million yuan decreased by 81.34% year-on-year
According to the Zhitong Finance App, Spike Health (00314) announced the results for the year ended December 31, 2023. The group obtained revenue of RMB 4.712 billion (same unit), an increase of 14.4% over the previous year; the owner of the parent company should have accounted for a loss of 256 million yuan, a decrease of 81.34% over the previous year; and a loss of 0.4 yuan per share. The company's specialty pharmacy business line operates specialty pharmacies and value-added professional pharmacist services, focusing on specialty drugs to treat tumors and other critical diseases. Patients can obtain innovative medicines from the company and receive pharmacist services, such as medication guidance, emergency consultation, and drug delivery. Duke
Sipai Health (00314.HK)'s annual revenue of 4.71 billion yuan increased 14.4% year-on-year
Gelonghui, March 19 | Spai Health (00314.HK) announced that for the year ended December 31, 2023, the company's revenue was 4.71 billion yuan, up 14.4% year on year; adjusted net loss was 150 million yuan, compared with a loss of 259 million yuan for the same period last year. The gross margin increased slightly from about 8.2% in 2022 to about 8.8% in 2023, mainly reflected in a sharp increase in the gross margin of the doctor research assistance service business and the relative stability of the gross margin of the health insurance service business.
SIPAI HEALTH: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
No Data